Scientific advisory board
AIMM’s Scientific Advisory Board includes prestigious leadership from the fields of cancer research, immunology and infectious disease.
Bob Löwenberg, MD, PhD
Erasmus University Rotterdam, the Netherlands
Renowned for his pivotal contributions to the diagnosis and treatment of acute myeloid leukemia, Bob Löwenberg has been chairman of the Department of Hematology at the Erasmus University Medical Center and currently serves as the editor-in-chief of Blood, the journal of the American Society of Hematology.
John Mendelsohn, MD, PhD
MD Anderson Cancer Center, Houston, USA
Following 5 years as president of the MD Anderson Cancer Center, John Mendelsohn currently serves as co-director of the Cancer Center’s Sheik Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy. Mendelsohn’s seminal work on epidermal growth factor receptors (EGFR) and the early clinical development of the cancer immunotherapy cetuximab (Erbitux) has led to the drug approvals by the FDA for the treatment of colon and head-and-neck cancer
Hidde Ploegh, PhD
Whitehead Institute, MIT, Cambridge, USA
World-leading immunologist, Hidde Ploegh is a faculty member at the Whitehead Institute for Biomedical Research and professor of biology at the Massachusetts Institute of Technology. The Ploegh Lab studies the various tactics that viruses employ to evade human immune responses and how the immune system distinguishes pathogens from healthy cells.
Menno de Jong, MD, PhD, FRCP Edin
Amsterdam Medical Center, University of Amsterdam, the Netherlands
Specializing in infectious disease research and emerging avian and human influenza infections, Menno de Jong heads the Department of Medical Microbiology at the Academic Medical Center, University of Amsterdam, is a professor of Clinical Virology and heads the Laboratory of Virology at the Oxford University Clinical Research Unit (OUCRU). In 1991, de Jong established the OUCRU at the Hospital for Tropical Diseases in Ho Chi Minh City, Vietnam.
Ton Schumacher, PhD
The Netherlands Cancer Institute
Using an engineering approach towards immunology, the Schumacher lab has provided seminal insights into how the T cell-based immune system recognizes human cancer cells, and how cancer-specific immune responses can be created. Schumacher is currently deputy director of The Netherlands Cancer Institute, professor of Immunotechnology at Leiden University, and Cancer Immunotherapy Dream Team member. The international initiative, Stand Up Cancer, has assembled interdisciplinary Dream Teams to advance translational research in the treatment of cancer.